Modern Pediatrics. Ukraine. (2022). 4(124): 84-90. doi 10.15574/SP.2022.124.84
Lazarenko I. F., Kurilina T. V., Hliadielova N. P.
Shupyk National Healthcare University of Ukraine, Kyiv

For citation: Lazarenko IF, Kurilina TV, Hliadielova NP. (2022). Hepatorenal syndrome in a child with cystic fibrosis: analysis of a clinical case. Modern Pediatrics. Ukraine. 4(124): 84-90. doi 10.15574/SP.2022.124.84.
Article received: Jan 28, 2022. Accepted for publication: Apr 20, 2022.

Hepato-renal syndrome (HRS) is a rare complication that may accompany end-stage cystic fibrosis-associated cirrhosis in patients with cystic fibrosis. There is currently no unified protocol for the diagnosis and treatment of HRS in cystic fibrosis, particularly in pediatric patients. The main approaches to diagnosing the condition are to detect signs of acute renal failure in a patient with severe liver damage in the absence of shock and in the absence of signs of organic kidney damage or the use of nephrotoxic drugs. Treatment is based on the appointment of vasoconstrictors in combination with albumin infusion and the exclusion of factors that promote the development of HRS, but the method of final therapy remains liver transplantation. The article presents an analysis of the clinical case of HRS and its treatment in a child with cystic fibrosis.
Immediate detection of liver cirrhosis in patients with cystic fibrosis, exclusion of the risk factors (massive and protracted surgical interventions, significant volume of extracted ascitic rudin, limiting the use of nephrotoxic drugs and high-dose loop diuretics) is a way to prevent the development of severe liver cirrhosis complications. Immediate recognition and proper management of HRS is a way to protect life before liver transplantation, as well as to preserve the quality of life of patients with cystic fibrosis.
The research was carried out in accordance with the principles of the Helsinki Declaration. The informed consent of the patient was obtained for conducting the studies.
No conflict of interests was declared by the authors.
Key words: cystic fibrosis, hepatorenal syndrome, liver cirrhosis, ascites, terlipressin.
REFERENCES
1. Acevedo JG, Cramp ME. (2017). Hepatorenal syndrome: Update on diagnosis and therapy. World journal of hepatology. 9 (6): 293-299. https://doi.org/10.4254/wjh.v9.i6.293; PMid:28293378 PMCid:PMC5332418

2. Allegretti AS, Solà E, Ginès P. (2020). Clinical Application of Kidney Biomarkers in Cirrhosis. American journal of kidney diseases: the official journal of the National Kidney Foundation. 76 (5): 710-719. https://doi.org/10.1053/j.ajkd.2020.03.016; PMid:32622560

3. Angeli P, Gines P, Wong F, Bernardi M, Boyer TD, Gerbes A, Moreau R, Jalan R, Sarin SK, Piano S, Moore K, Lee SS, Durand F, Salerno F, Caraceni P, Kim WR, Arroyo V, Garcia-Tsao G, International Club of Ascites. (2015). Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. Gut. 64 (4): 531-537. https://doi.org/10.1136/gutjnl-2014-308874; PMid:25631669

4. Arroyo V, Fernandez J, Ginès P. (2008). Pathogenesis and treatment of hepatorenal syndrome. Seminars in liver disease. 28 (1): 81-95. https://doi.org/10.1055/s-2008-1040323; PMid:18293279

5. Arroyo V, Ginès P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, Reynolds TB, Ring-Larsen H, Schölmerich J. (1996). Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology (Baltimore, Md.). 23 (1): 164-176. https://doi.org/10.1002/hep.510230122; PMid:8550036

6. Boyer TD, Sanyal AJ, Wong F, Frederick RT, Lake JR et al. (2016, Jun). Terlipressin Plus Albumin. Gastroenterology. 150(7): 1579-1589.e2. Epub 2016 Feb 16. https://doi.org/10.1053/j.gastro.2016.02.026; PMid:26896734

7. Chaney A. (2021). A Review for the Practicing Clinician: Hepatorenal Syndrome, a Form of Acute Kidney Injury, in Patients with Cirrhosis. Clin Exp Gastroenterol. 14: 385-396. https://doi.org/10.2147/CEG.S323778; PMid:34675586 PMCid:PMC8502008

8. Drobova NM, Yanovska KO, Pasichnyk OV, Klymenko VA et al. (2017). The clinical case of the child with cystic fibrosis and multiple organ failure syndrome development. Sovremennaya pediatriya. 5(85): 132-136. https://doi.org/10.15574/SP.2017.85.132

9. European Association for the Study of the Liver (EASL). (2018). Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 69(2): 406-460. https://doi.org/10.1016/j.jhep.2018.08.009; Mid:30172388

10. Facciorusso A. (2019). Hepatorenal Syndrome Type 1: Current Challenges And Future Prospects. Therapeutics and clinical risk management. 15: 1383-1391. https://doi.org/10.2147/TCRM.S205328; PMid:31819465 PMCid:PMC6886557

11. Raina R, Sethi SK, Filler G, Menon S, Mittal A et al. (2022). PCRRT Expert Committee ICONIC Position Paper on Prescribing Kidney Replacement Therapy in Critically Sick Children With Acute Liver Failure. Front. Pediatr. 9: 833205. https://doi.org/10.3389/fped.2021.833205; PMid:35186830 PMCid:PMC8849201

12. Saxena, R., Anand, A. & Deep, A. Use of terlipressin in critically ill children with liver disease. BMC Nephrol 21, 360 (2020). https://doi.org/10.1186/s12882-020-01914-6; PMid:32819297 PMCid:PMC7441708

13. Simonetto DA, Gines P, Kamath PS. (2020). Hepatorenal syndrome: pathophysiology, diagnosis, and management BMJ. 370: m2687. https://doi.org/10.1136/bmj.m2687; PMid:32928750

14. Subedi A, Suresh Kumar VC, Sharma Subedi A, Sapkota B. (2021). A Review of Hepatorenal Syndrome. Cureus. 13 (7): e16084. https://doi.org/10.7759/cureus.16084

15. Tariq R, Singal AK. (2020). Management of hepatorenal syndrome: a review. J Clin Transl Hepatol. 8(2): 192-199. https://doi.org/10.14218/JCTH.2020.00011; PMid:32832400 PMCid:PMC7438356

16. Wong F, Blendis L. (2021). Historical Aspects of Ascites and the Hepatorenal Syndrome. Clinical liver disease. 18 (1): 14-27. https://doi.org/10.1002/cld.1090; PMid:34745581 PMCid:PMC8555459